Update on Admission of Shares
Hemogenyx Pharmaceuticals plc has announced that the Financial Conduct Authority has scheduled the admission hearing for new ordinary shares for January 5, 2026, with admission expected on January 6, 2026. All other details from the December 18, 2025 announcement remain unchanged.
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 2025.
The FCA has notified the Company that the admission hearing has been scheduled for the earliest available date being 5 January 2026, with admission expected to occur on or around 8.00 a.m. on 6 January 2026.
All other details outlined in the Company's announcement of 18 December 2025 remain unchanged.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.